588PEfficacy and safety of FOLFIRI/Aflibercept (FA) in elderly population with mCRC after failure of oxaliplatin-based chemotherapy

ConclusionsOlder patients with mCRC are underrepresented in clinical trials. The VELOUR study included only 6.4% pts>75y of age and only 14% included in the substudy of patients>65y were>75y. Patients>65y treated with FA in the VELOUR trial experienced a high rate of G3-4 adverse events (89.3%). Our series confirms that with careful pt selection and dose adjustment based on toxicity, patients>70y can be treated with FA with a 52.0% of grade 3-4 toxicity, results that are comparable to those of younger patients.Legal entity responsible for the studyGalician Research Group on Digestive Tumours (GITuD).FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research